Int J Cancer: REBACIN ® as a noninvasive clinical intervention for persistent infection of high-risk human papillomavirus.

The development of highly sensitive HPV genotyping tests has made it possible to treat hpV-infected women before high-risk lesions occur.
lack of effective interventions for persistent high-risk HPV infections, new treatment strategies need to be developed.
, we have demonstrated the ® reBACIN, a proprietary antiviral biologic, that is effective in removing persistent HPV infections.
we conducted two separate parallel clinical studies, which included 199 patients and were randomly divided into REBACIN® trial groups and untreated control groups.
two separate parallel studies, the virus clearance rate in the REBACIN ® group was 61.5% (24/39) and 62.5% (35/56), respectively.
, the self-purge rate in the non-therapeutic group was 20.0 per cent (8/40) and 12.5 per cent (8/64).
further studies have found that REBACIN ® significantly inhibit the expression of HPV E6 and E7 cancer genes in TC-1 and Hela cells.
in mouse models, REBACIN® significantly inhibited E6/E7-induced tumor growth, indicating that the E6 and E7 carcinogenic genes were potential targets for REBACIN ®.
, our research provides an effective way to develop new non-invasive treatment interventions to eliminate persistent HPV infections.
.